Clinical Research Programs:
Rheumatoid Arthritis
MUSICA: Open-label Humira, studying the effects of a low or high dose of methotrexate. Efficacy tested by ultrasound.
To pre-qualify for this trial,
- you must:
- have at least 4 swollen and tender joints.
- currently be on an oral methotrexate dose of 15-20 mg/week for at least 12 weeks.
- be taking prednisone. Dose must be less than 5 mg/day.
- you must not:
- not currently be taking hydroxychloroquine, sulfasalazine, plaquenil, or leflunomide.
- have any previous exposure to biologics.
- have had a diagnosis of Junior Rheumatoid Arthritis.
- have had a diagnosis of gout or pseudogout.
- This study last for six months — one visit every month, plus a screening visit.
To learn more, please call (206) 368.6135.
BATTER-UP: Biomarkers of anti-Tumor Necrosis Factor (anti-TNF) therapy efficacy in rheumatoid arthritis to define unresponsive patients. A questionnaire and blood draw only study. No drug is given.
To pre-qualify for this trial,
- you must:
- have at least 4 swollen and tender joints.
- be about to start treatment with your first anti-tumor necrosis factor (anti-TNF) agent or about to start a second anti-TNF agent to treat your RA.
- you must not have had any:
- exposure to 2 or more anti-TNF agents.
- prior exposure to Orencia, abatacept, or CTLA4-Ig, and/or Rituxan, or other biologic therapies for RA or other diseases.
- This study last for three visits:
- Visit 1: Occurs before first dose of anti-TNF
- Visit 2: Occurs 14 weeks after the first dose has been taken
- Visit 3: A follow-up phone call.
To learn more, please call (206) 368.6135.
Questions?
Questions regarding research can be directed to:
Tammy Stacy
MA, CRC
(206) 368.6135